Nisa Investment Advisors
MGX icon

Nisa Investment Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Nisa Investment Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-511
Closed -$685 – 3192
2026
Q1 		$685 Hold
511
– – ﹤0.01% 2813
2025
Q4 		$828 Hold
511
– – ﹤0.01% 2739
2025
Q3 		$1.21K Sell
511
-117
-19% -$237 ﹤0.01% 2710
2025
Q2 		$929 Buy
628
+95
+18% +$149 ﹤0.01% 2749
2025
Q1 		$725 Sell
533
-12
-2% -$29 ﹤0.01% 2719
2024
Q4 		$1.97K Buy
545
+537
+6,713% +$1.3K ﹤0.01% 2491
2024
Q3 		$17 Buy
+8
New +$28 ﹤0.01% 2954

Other funds holding MGX

PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
FAG
Fortitude Advisory Group Gig Harbor, Washington $262M AUM 42.09% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Nisa Investment Advisors's MGX Position: Q2 2026 in Review

Nisa Investment Advisors sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 511 shares — an estimated $685 sold.

Nisa Investment Advisors first reported a position in MGX in Q3 2024 and held it in 7 quarters. The position peaked at $1.97K in Q4 2024. 7 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Nisa Investment Advisors reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nisa Investment Advisors sold 511 Metagenomi Therapeutics shares in Q2 2026, an estimated $685.
  • Nisa Investment Advisors first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 7 quarters.
  • Nisa Investment Advisors's Metagenomi Therapeutics position peaked at $1.97K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.